(90 days)
None
No
The summary does not mention any AI or ML capabilities, and the device description focuses on the laser technology and hardware components. The performance studies section indicates equivalence to predicate devices without mentioning any AI/ML-driven features.
Yes
The device is indicated to "promote hair growth" for a specific medical condition (androgenetic alopecia), which implies a therapeutic effect.
No
The device is indicated to promote hair growth, which is a therapeutic function, not a diagnostic one. It does not identify or detect conditions.
No
The device description explicitly states it consists of diode lasers configured within an outer cap helmet and protective inner liner, powered by a lithium-ion battery pack. These are hardware components, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is to "promote hair growth in females with androgenetic alopecia... and males who have Norwood-Hamilton Classifications...". This is a therapeutic use, not a diagnostic one.
- Device Description: The device is a laser cap that applies light to the scalp. This is a physical intervention, not a test performed on biological samples.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (like blood, urine, tissue, etc.), detecting specific analytes, or providing diagnostic information.
IVD devices are used to examine specimens derived from the human body to provide information for the diagnosis, prevention, or treatment of a disease or condition. This device's function is to directly treat a condition (hair loss) through light therapy.
N/A
Intended Use / Indications for Use
The Grivamax Family of Lasers, Models 272 and 148 are indicated to promote hair growth in females with androgenetic alopecia who have Ludwig-Savin Classifications of I - II, males who have Norwood-Hamilton Classifications of IIa - V and for both, Fitzpatrick Classification of Skin Phototypes I to IV.
Product codes
OAP
Device Description
The Grivamax Family of Lasers, Models 272 and 148 consist of 272 diode lasers or 148 diode lasers configured within an outer cap helmet and protective inner liner. The use of diode lasers provides for a full coverage of the upper 1/3 of the head i.e., the area commonly covered with stylized hair. The Grivamax Family of Lasers, Models 272 and 148 are powered by a lithium-ion battery pack that contains an embedded controller chip.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
upper 1/3 of the head
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Over-The-Counter Use (21 CFR 801 Subpart C)
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
No clinical performance data was produced for this submission because the Grivamax Family of Lasers, Models 272 and 148 are the same device as the Cleared predicates, the Diode Laser Cap (K173678) and the Grivamax Hair Growth System(K171895).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
None
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 890.5500 Infrared lamp.
(a)
Identification. An infrared lamp is a device intended for medical purposes that emits energy at infrared frequencies (approximately 700 nanometers to 50,000 nanometers) to provide topical heating.(b)
Classification. Class II (special controls). The device, when it is an infrared therapeutic heating lamp, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 890.9.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food & Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" in a square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in a sans-serif font.
July 20, 2021
Leana Orders, Inc % Raymond Blanche Consultant NST Consultants, Inc. 5 Cold Hill Road South, Unit 12 Mendham, New Jersey 07945
Re: K211192
Trade/Device Name: Grivamax Family of Lasers, Models 272 and 148 Regulation Number: 21 CFR 890.5500 Regulation Name: Infrared Lamp Regulatory Class: Class II Product Code: OAP Dated: February 17, 2021 Received: April 21, 2021
Dear Raymond Blanche:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Purva Pandya Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Section 4
Indications for Use Statement
FDA Form 3881
3
Indications for Use
510(k) Number (if known)
K211192
Device Name Grivamax Family of Lasers, Models 272 and 148
Indications for Use (Describe)
The Grivamax Family of Lasers , Models 272 and 148 are indicated to promote hair growth in females with androgenetic alopecia who have Ludwig-Savin Classifications of I - II, males who have Norwood-Hamilton Classifications of IIa - V and for both, Fitzpatrick Classification of Skin Phototypes I to IV.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
510(k) Summary for K211192 Leana Orders, Inc.
Submitter's Contact Information
| Name: | Raymond R. Blanche |
|---|---|
| Address | NST Consultants, Inc |
| 5 Cold Hill Road South | |
| Unit 12 | |
| Mendham, New Jersey 07945 | |
| Telephone: | |
| Facsimile: | (973)531-6226 |
| (973)539-7445 |
Name of Device and Name/Address of Sponsor
| Trade Name: | Grivamax Family of Lasers, Models, 272 and 148 |
|---|---|
| Sponsor Contact | |
| Information: | Leonid Krits |
| Leana Orders, Inc. | |
| 12 Jefferson Boulevard | |
| Suite 1F | |
| Staten Island, NY 10312 | |
| Telephone: | 718-415-1901 |
| Common or Usual Name: | Lamp, non-heating, for promotion of hair growth |
| Classification Name: | Infrared lamp per 21 CFR 890.5500 |
| Classification Code: | OAP (Laser, comb, hair) |
Predicate Devices:
Device Trade Name
Diode Laser Cap (K173678) Grivamax Hair Growth System (K171895)
Reference Devices:
None
Manufacturer
Cosmo Far East Technology Limited Cosmo Far East Technology Limited
5
Date Prepared: July 20, 2021 Revised
Intended Use / Indications for Use
The Grivamax Family of Lasers, Models, 272 and 148 are indicated to promote hair growth in females with androgenetic alopecia who have Ludwig-Savin Classifications of I - II, males who have Norwood-Hamilton Classifications of IIa - V and for both, Fitzpatrick Classification of Skin Phototypes I to IV.
Technological Characteristics
The Grivamax Family of Lasers, Models 272 and 148 consist of 272 diode lasers or 148 diode lasers configured within an outer cap helmet and protective inner liner. The use of diode lasers provides for a full coverage of the upper 1/3 of the head i.e., the area commonly covered with stylized hair. The Grivamax Family of Lasers, Models 272 and 148 are powered by a lithium-ion battery pack that contains an embedded controller chip.
Performance Data:
No clinical performance data was produced for this submission because the Grivamax Family of Lasers, Models 272 and 148 are the same device as the Cleared predicates, the Diode Laser Cap (K173678) and the Grivamax Hair Growth System(K171895). Both predicates are IDENTICAL devices offered for PRIVATE LABEL by the manufacturer, Cosmo Far East Technology Limited. They are the same device in optical, electronic, mechanical function and aesthetic appearance, as well as the same recommended clinical treatment regime.
Substantial Equivalence
Both the proposed devices, of which the Grivamax Hair Growth System is Cleared under (K171895) and the Diodes Laser Cap, Cleared under (K173678) use red light diode lasers are classified as class IIIa/3R laser systems by the IEC standard for allowable emission levels, which is a recognized standard by the FDA as well, and the adverse event profile is the same. The sponsor believes that there is no difference in the physical appearance or in the method of delivering the radiant energy of the two systems and therefore, there are no variations in the therapeutic value or safety profile.
Finally, the summarized data contained in the Predicates and Proposed devices in the following chart confirms the safety and efficacy of the device and accordingly, the Proposed devices, Grivamax Family of Lasers, Models 272 and 148 should be granted a 510(k) Clearance for Overthe-Counter Use per Part 21 CFR 801 Subpart C. For these reasons, the Grivamax Family of Lasers, Models 272 and 148 overwhelmingly satisfy the FDA's substantial equivalence with respect to intended use, technological and design characteristics.
6
Treatment Protocol
The Grivamax Family of Lasers, Models 272 and 148 and the Diode Laser Cap devices possess the same treatment regime of 30 minutes, every other day, on non-consecutive days, for the initial treatment regime of 16 weeks.
The following Comparison Chart in support of substantial equivalence is provided:
| Specification Category | Grivamax Family of Lasers
Models 272 and 148 | Diode Laser Cap (K173678 )
Grivamax Hair Growth Lasers (K171895) |
|------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| | (K211192) | Models 272 and 148 |
| | Proposed Device for OTC Use | Predicate with OTC Indication for Use |
| LLLT Device Type | Laser Diode | Laser Diode |
| Use Application | OTC | OTC |
| Intended Use Androgenetic Alopecia | Androgenetic Alopecia | Androgenetic Alopecia |
| Contain Laser Diodes-Class 3R | 272, 148, 5 milliwatts each. | 272, 148, 5 milliwatts each. |
| Physical Design of Device | Helmet | Helmet |
| Wavelength | 650+/-5 NMS. | 650+/-5 NMS. |
| Marketing Clearance | For females and males, OTC | For females and males OTC |
| Use Type | Passive Use-Hands Free | Passive Use-Hands Free |
| Classification Code | OAP | OAP |
| Classification Name | Infrared Lamp | Infrared Lamp |
| Common Usage Name | Lamp, Non-Heating | Lamp, Non-Heating |
| Classification Panel | General & Plastic Surgery | General & Plastic Surgery |
| Skin Phototypes | I- IV | I- IV |
| Hair Loss Classification | Hamilton-Norwood IIa-V for males
Ludwig-Savin I - II for females | Hamilton-Norwood IIa-V for males
Ludwig-Savin I - II Hair for females |
| Treatment Regime | 16 weeks, for 30-minute treatment times
three times a week, on alternate days. | 16 weeks, for 30-minute treatment times
three times a week, on alternate days. |
| Device Class | II | II |
With the data presented in the Comparison Chart, the sponsor believes that this data demonstrates that the devices are identical and equivalent, PRIVATE LABEL devices from the same manufacturer and therefore are identical because the manufacturer ONLY produces these models.
Based on this comparison and determination, the sponsor requests the FDA to clear the device via the 510(k) notice.
7
Over - The - Counter Testing Program
No OTC testing was performed for this submission because the User Manual and packaging contents for the predicates. While some of the language contained in the User Manuals of the Proposed devices may differ, these differences do not alter the Self Selection. Hazards and Precautions, or Usability criteria. The only major exception is color and logo of the subject device literature. The graphic changes do not alter the content of the User Manual, the key variable in any OTC testing evaluation. The aesthetic appearance of the proposed devices, the predicates devices and the reference devices all use the same exterior black shell and interior clear shells. The dimensions of the shells are also equivalent.
Electrical Safety and Electromagnetic Compatibility Testing Performance
The Grivamax Family of Lasers, Models 272 and 148 were not evaluated for conformance to recognized international standards.
Biocompatibility, electrical safety and EMC testing is not needed in this submission because the subject device is identical to the predicate devices in these aspects.
Shelf Life
The Usable life expectancy for this device is 10.000 hours based on the specifications for the laser diode and 5 years for the overall usable life of the Grivamax Family of Lasers, Models 272 and 148
Electrical Safety Testing Performance
The Grivamax Hair Growth System and Diode Laser Cap were evaluated for conformance to recognized international standards. The following is a list of these evaluations and tests that were found to be in conformance:
-
- IEC 60825-1 Edition 3.0 2014 Safety of Laser Products Part 1: Equipment Classification and Requirements.
-
- IEC 60601-1-2-22 Edition 3.1 2012-10 Basic Safety and Essential Performance
Conclusion
Based on the technical comparisons between the Grivamax Hair Growth Lasers (K171895) and the Diode Laser Cap (K173678) which are the same as the Proposed devices, it can be concluded that the proposed devices are substantially equivalent to the predicate devices in technical specifications. Since the proposed devices are currently being marketed with an OTC Indication for Use, therefore, with no modifications in manufacturing, the proposed devices and predicates do not raise any issues of safety or efficacv.
The summary includes the conclusions drawn from the nonclinical tests ((discussed above) that demonstrate that the devices are as safe and as effective and perform as well as or better than the predicate devices.